Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eczema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    342 result(s) found for: eczema. Displaying page 8 of 18.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2020-004767-77 Sponsor Protocol Number: IM018-005 Start Date*: 2021-10-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000839-17 Sponsor Protocol Number: CASM981C2439 Start Date*: 2005-04-11
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant ...
    Medical condition: Treatment of severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012438 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003689-26 Sponsor Protocol Number: CLS001-CO-PR-00;CHDR1428 Start Date*: 2015-04-16
    Sponsor Name:Cutanea Life Sciences
    Full Title: A randomized, double-blind, placebo controlled study to assess the pharmacodynamics, safety/tolerability and efficacy of omiganan in patients with mild to moderate atopic dermatitis
    Medical condition: Patients with mild to moderate atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    17.1 100000004858 10003640 Atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022280-35 Sponsor Protocol Number: SSD113434 Start Date*: 2010-11-22
    Sponsor Name:GlaxoSmithKline
    Full Title: A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis.
    Medical condition: subjects with moderate or severe atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006422-33 Sponsor Protocol Number: ASAC-ANADA-1-08 Start Date*: 2009-07-22
    Sponsor Name:Especialidades Farmacéuticas Centrum, S.A
    Full Title: Ensayo clínico, aleatorizado, doble ciego, controlado con placebo, de la eficacia de Anapsos® en la reducción del empleo de corticosteroides tópicos en el tratamiento de la dermatitis atópica moder...
    Medical condition: Pacientes diagnosticados de dermatitis atópica según los criterios de Hanifin y Rajka, con índice SCORAD de 20 a 40, ambos inclusive, que utilicen o en quienes se indique el empleo de corticosteroi...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012438 Dermatitis atopic LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002194-10 Sponsor Protocol Number: RV4421A2013147 Start Date*: 2014-11-10
    Sponsor Name:Pierre Fabre Dermo-Cosmétique
    Full Title: An intra-individual randomized controlled study to evaluate the efficacy and tolerance of the product RV4421A BS0042 in association with a moderately potent topical corticosteroid in adults with At...
    Medical condition: Atopic Dermatitis (arms, popliteal fossa)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022864-12 Sponsor Protocol Number: AA-10-1.01 Start Date*: 2011-04-20
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab ...
    Medical condition: Disease to be investigated: 12 patients with severe chronic urticaria (CU) with or without angioedema which continously need medical treatment As a control: 6 patients with atopy syndrome consisti...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009159 Chronic urticaria LLT
    12.1 10021247 Idiopathic urticaria LLT
    12.1 10003639 Atopic dermatitis LLT
    12.1 10031673 Other atopic dermatitis and related conditions LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001574-42 Sponsor Protocol Number: FPC117291 Start Date*: 2017-09-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, open-label, comparative study to evaluate an intermittent dosing regimen of fluticasone propionate 0·05% cream (twice per week) in reducing the risk of relapse when added to regular d...
    Medical condition: stabilized atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000018018 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002838-46 Sponsor Protocol Number: DS107E-05 Start Date*: Information not available in EudraCT
    Sponsor Name:DS Biopharma
    Full Title: A prospective, randomised, vehicle-controlled, double-blind, exploratory clinical trial to assess the efficacy and steroid sparing potential of DGLA cream topically applied to early childhood patie...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000229-24 Sponsor Protocol Number: RD.06.SPR.201593 Start Date*: 2021-02-23
    Sponsor Name:Galderma S.A.
    Full Title: An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Moderate-to-severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000873-35 Sponsor Protocol Number: I4V-MC-JAHN Start Date*: 2017-10-27
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) AT (Completed) ES (Ongoing) PL (Completed) FR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004574-34 Sponsor Protocol Number: I4V-MC-JAIN Start Date*: 2018-04-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moder...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) AT (Completed) BE (Completed) PL (Completed) FI (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001924-20 Sponsor Protocol Number: OC000459/017/13 Start Date*: 2013-07-24
    Sponsor Name:Atopix Therapeutics Ltd.
    Full Title: A study of the effect of OC000459 on signs & symptoms in subjects with moderate to severe atopic dermatitis: A randomised double blind placebo controlled parallel group study
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) AT (Completed) CZ (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002264-57 Sponsor Protocol Number: M16-046 Start Date*: 2019-07-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermat...
    Medical condition: moderate to severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) GB (GB - no longer in EU/EEA) NL (Completed) SE (Completed) FR (Completed) HU (Completed) NO (Completed) ES (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002344-73 Sponsor Protocol Number: LTS17367(KY1005-CT06) Start Date*: 2022-07-12
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis who participated ...
    Medical condition: Dermatitis atopic
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003610-12 Sponsor Protocol Number: B7451064 Start Date*: 2021-06-16
    Sponsor Name:Pfizer Inc.
    Full Title: ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
    Medical condition: Moderate to severe atopic dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) ES (Ongoing) GR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004467-29 Sponsor Protocol Number: Start Date*: 2005-07-27
    Sponsor Name:Craigavon Area Hospital Group Trust
    Full Title: An open label pilot study to evaluate the efficacy and safety of topical tacrolimus 0l1% (Protopic) in the treatment of varicose eczema
    Medical condition: Varicose eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002619-40 Sponsor Protocol Number: R668-AD-1416 Start Date*: 2015-03-25
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) IT (Completed) GB (Completed) SE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001888-75 Sponsor Protocol Number: RD.06.SPR.118169 Start Date*: 2020-07-28
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001887-31 Sponsor Protocol Number: RD.06.SPR.118161 Start Date*: 2020-02-19
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) GB (GB - no longer in EU/EEA) DE (Completed) LT (Completed) NL (Completed) AT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 12:25:12 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA